Yingcheng Wang
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: November 05, 2022
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Journal: Frontiers in public health
Published: May 30, 2022
Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
Journal: Journal of medical economics
Published: April 27, 2022
The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China.
Journal: Frontiers in pharmacology
Published: January 26, 2022
Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis.
Journal: Frontiers in medicine
Published: March 11, 2021
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: March 11, 2021
Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.
Journal: Frontiers in medicine
Published: January 26, 2021
Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China.
Journal: Frontiers in medicine
Published: January 23, 2021
Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US.
Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US.
Journal: Frontiers in public health
Published: January 07, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026